通心络防治急性心肌梗死再灌注后无再流研究进展  

Research progress of Tongxinluo capsule in preventing and treating no-reflow after acute myocardial infarction and reperfusion

作　　者：袁国强[1] 常成成 张凤虹 李红蓉(综述) 洪衡(审校) Yuan Guoqiang;Chang Chengcheng;Zhang Fenghong;Li Hongrong;Hong Heng(Department of Cardiology,Yiling Hospital,Hebei Province,Shijiazhuang 050091,China;不详)

机构地区：[1]河北以岭医院心血管病科/国家中医药管理局中医络病学重点学科,石家庄050091 [2]河北省中医心血管疾病临床医学研究中心 [3]络病研究与创新中药国家重点实验室,050000

出　　处：《疑难病杂志》2023年第2期208-211,共4页Chinese Journal of Difficult and Complicated Cases

基　　金：国家重点研发计划“中医药现代化研究”重点专项(2017YFC1700500);河北省重点研发计划项目中医药创新专项(223777120D)。

摘　　要：急性心肌梗死再灌注后无再流可导致心肌彻底坏死、心肌梗死面积扩大,心脏功能受损,左心室重构和心力衰竭,严重影响患者近远期预后,成为心血管界的一大国际难题和研究热点。络病理论代表方药通心络胶囊对心肌无再流的治疗优势日益显现,文章综述了近10余年应用通心络防治该病的有关基础与临床研究方面的进展。Non-reflow after acute myocardial infarction and reperfusion can lead to complete myocardial necrosis,expansion of myocardial infarction area,damage of cardiac function,left ventricular remodeling and heart failure,which seriously affect the short-term and long-term prognosis of patients,and become a major international problem and research hotspot in the cardiovascular field.Tongxinluo capsule,the representative prescription of collateral disease theory,has increasingly shown its advantages in the treatment of myocardial no-reflow.This article reviews the progress of basic and clinical research on the application of Tongxinluo capsule in the prevention and treatment of this disease in the past 10 years.

关 键 词：心肌梗死 急性 无再流 络病理论 通心络 

分 类 号：R542.2[医药卫生—心血管疾病]